These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38927979)

  • 1. Prediction of Efficacy for Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma with Hepatobiliary-Phase Gadolinium Ethoxybenzyl-Diethylenetriaminepentaacetic Acid MRI.
    Kunichika H; Minamiguchi K; Tachiiri T; Shimizu K; Taiji R; Yamada A; Nakano R; Irizato M; Yamauchi S; Marugami A; Marugami N; Kishida H; Nakagawa H; Takewa M; Kageyama K; Yamamoto A; Ueshima E; Sofue K; Kita R; Kurakami H; Tanaka T
    Cancers (Basel); 2024 Jun; 16(12):. PubMed ID: 38927979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma.
    Sasaki R; Nagata K; Fukushima M; Haraguchi M; Miuma S; Miyaaki H; Soyama A; Hidaka M; Eguchi S; Shigeno M; Yamashima M; Yamamichi S; Ichikawa T; Kugiyama Y; Yatsuhashi H; Nakao K
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of early recurrence of hepatocellular carcinoma after resection based on Gd-EOB-DTPA enhanced magnetic resonance imaging: a preliminary study.
    Zhao QY; Liu SS; Fan MX
    J Gastrointest Oncol; 2022 Apr; 13(2):792-801. PubMed ID: 35557582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.
    Aoki T; Nishida N; Ueshima K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Minami Y; Yamada A; Sofue K; Tsurusaki M; Kudo M
    Liver Cancer; 2021 Nov; 10(6):615-628. PubMed ID: 34950184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Analysis of Signal Heterogeneity in the Hepatobiliary Phase of Pretreatment Gadoxetic Acid-Enhanced MRI as a Prognostic Imaging Biomarker in Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma.
    Minamiguchi K; Nishiofuku H; Saito N; Sato T; Taiji R; Matsumoto T; Maeda S; Chanoki Y; Tachiiri T; Kunichika H; Inoue T; Marugami N; Tanaka T
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of lenvatinib for hepatocellular carcinoma with iso-high intensity in the hepatobiliary phase of Gd-EOB-DTPA-MRI.
    Kuwano A; Tanaka K; Yada M; Nagasawa S; Morita Y; Masumoto A; Motomura K
    Mol Clin Oncol; 2022 Feb; 16(2):53. PubMed ID: 35070302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of vessels encapsulating tumor clusters pattern and prognosis of hepatocellular carcinoma based on preoperative gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic acid magnetic resonance imaging.
    Wang M; Cao L; Wang Y; Huang H; Cao S; Tian X; Lei J
    J Gastrointest Surg; 2024 Apr; 28(4):442-450. PubMed ID: 38583894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced magnetic resonance imaging for evaluating fibrosis regression in chronic hepatitis C patients after direct-acting antiviral.
    Li XH; Huang R; Yang M; Wang J; Gao YH; Jin Q; Ma DL; Wei L; Rao HY
    World J Gastroenterol; 2022 May; 28(20):2214-2226. PubMed ID: 35721884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary-phase gadolinium ethoxybenzyl-diethylenetriaminepentaacetic acid MRI for pretreatment prediction of efficacy-to-standard-therapies based on Barcelona Clinic Liver Cancer algorithm: an up-to-date review.
    Minamiguchi K; Irizato M; Uchiyama T; Taiji R; Nishiofuku H; Marugami N; Tanaka T
    Eur Radiol; 2023 Dec; 33(12):8764-8775. PubMed ID: 37470828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The predictive value of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid enhanced MRI imaging features combined with quantitative parameters for the pathologic grading of hepatocellular carcinoma].
    Hu MJ; Yu YX; Fan YF; Jiang YM; Hu S; Wang XM; Hu CH
    Zhonghua Yi Xue Za Zhi; 2020 May; 100(17):1299-1304. PubMed ID: 32375436
    [No Abstract]   [Full Text] [Related]  

  • 11. Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma.
    Mao Y; Wang J; Zhu Y; Chen J; Mao L; Kong W; Qiu Y; Wu X; Guan Y; He J
    Hepatobiliary Surg Nutr; 2022 Feb; 11(1):13-24. PubMed ID: 35284527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coefficient of variation on Gd-EOB MR imaging: Correlation with the presence of early-stage hepatocellular carcinoma in patients with chronic hepatitis B.
    Lee JH; Kim YR; Lee GM; Ryu JH; Cho EY; Lee YH; Yoon KH
    Eur J Radiol; 2018 May; 102():95-101. PubMed ID: 29685552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating mass-forming intrahepatic cholangiocarcinoma from atypical hepatocellular carcinoma using Gd-EOB-DTPA-enhanced magnetic resonance imaging combined with serum markers in at-risk patients with hepatitis B virus.
    Han D; Li Y; He X; Zhang J; Zhou Y; Zhang J; Zhang L
    Quant Imaging Med Surg; 2023 Oct; 13(10):7156-7169. PubMed ID: 37869332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gd-EOB-DTPA-enhanced magnetic resonance imaging features of hepatic hemangioma compared with enhanced computed tomography.
    Tateyama A; Fukukura Y; Takumi K; Shindo T; Kumagae Y; Kamimura K; Nakajo M
    World J Gastroenterol; 2012 Nov; 18(43):6269-76. PubMed ID: 23180948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
    Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
    Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical association between intraoperative indocyanine green fluorescence imaging pattern, preoperative Gd-EOB-DTPA-enhanced magnetic resonance imaging findings, and histological differentiation in hepatocellular carcinoma.
    Tomino T; Itoh S; Fujita N; Okamoto D; Nakayama Y; Toshida K; Tomiyama T; Tsutsui Y; Kosai Y; Kurihara T; Nagao Y; Morita K; Harada N; Ushijima Y; Kohashi K; Ishigami K; Oda Y; Yoshizumi T
    Hepatol Res; 2023 Aug; 53(8):723-736. PubMed ID: 36998205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of non-hypervascular hypointense nodules on Gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in patients with hepatocellular carcinoma.
    Inoue M; Ogasawara S; Chiba T; Ooka Y; Wakamatsu T; Kobayashi K; Suzuki E; Tawada A; Yokosuka O
    J Gastroenterol Hepatol; 2017 Apr; 32(4):908-915. PubMed ID: 27787908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging features based on Gd-EOB-DTPA-enhanced MRI for predicting vessels encapsulating tumor clusters (VETC) in patients with hepatocellular carcinoma.
    Fan Y; Yu Y; Hu M; Wang X; Du M; Guo L; Hu C
    Br J Radiol; 2021 Mar; 94(1119):20200950. PubMed ID: 33417489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment.
    Tamura Y; Ono A; Nakahara H; Hayes CN; Fujii Y; Zhang P; Yamauchi M; Uchikawa S; Teraoka Y; Uchida T; Fujino H; Nakahara T; Murakami E; Tsuge M; Serikawa M; Miki D; Kawaoka T; Okamoto W; Imamura M; Nakamura Y; Awai K; Kobayashi T; Ohdan H; Fujita M; Nakagawa H; Chayama K; Aikata H; Oka S
    Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.